原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系

摘要/Abstract

摘要： 目的检测原发性肝癌患者血清长链非编码RNA人母系表达基因(LncRNA-MEG3)的表达情况,并探究其表达水平与原发性肝癌患者预后的相关性。方法选取2015年4月至2016年11月西京医院收治的原发性肝癌患者68例为原发性肝癌组,同期选取在本院进行常规体检的健康人群70例为对照组。采用实时荧光定量PCR法(qRT-PCR)检测所有研究对象血清LncRNA-MEG3的表达水平。分析血清LncRNA-MEG3表达水平与原发性肝癌临床病理特征之间的关系;通过Kaplan-Meier法绘制生存曲线评估血清LncRNA-MEG3表达水平对原发性肝癌患者预后的影响;采用Cox回归分析原发性肝癌患者预后的影响因素。结果原发性肝癌组血清LncRNA-MEG3表达水平显著低于对照组(P<0.05)。原发性肝癌患者血清LncRNA-MEG3表达与临床分期、分化程度及肝硬化密切相关(P<0.05),而与患者性别、年龄、肿瘤直径无明显相关性(P>0.05)。血清LncRNA-MEG3低表达组治疗后3年总生存率均显著低于高表达组(P<0.05)。Cox回归分析结果显示,LncRNA-MEG3低表达和临床分期是影响原发性肝癌患者预后的独立危险因素(HR=2.500,95%CI为1.624~3.849;HR=2.024,95%CI为1.307~3.135,P均＜0.05)。结论 LncRNA-MEG3在原发性肝癌患者血清中的表达水平明显降低,且与患者临床分期、分化程度及肝硬化及患者预后密切相关,提示LncRNA-MEG3或许可作为原发性肝癌病情评估及不良预后预测的潜在生物学指标。

关键词: 原发性肝癌, 长链非编码RNA人母系表达基因, 临床病理特征, 预后

Abstract: Objective To detect the expression of long non-coding RNA maternally expressed gene 3 (LncRNA-MEG3) in serum of patients with primary liver cancer, and to explore the correlation between the expression level and the prognosis of patients with primary liver cancer. Methods From April 2015 to November 2016, 68 patients with primary liver cancer in our hospital were selected as the primary liver cancer group, and 70 healthy people who had routine physical examination in our hospital were selected as the control group. The expression level of serum LncRNA-MEG3 was detected by quantitative real-time polymerase chain reaction. The relationship between the serum expression level of LncRNA-MEG3 and the clinicopathological characteristics of primary liver cancer was analyzed. The influence of serum LncRNA-MEG3 expression level on the prognosis of patients with primary liver cancer was evaluated by Kaplan-Meier curve. The prognostic factors of patients with primary liver cancer were analyzed by Cox regression analysis. Results The serum expression level of LncRNA-MEG3 in the primary liver cancer group was significantly lower than that in the control group (P<0.05). The serum expression of LncRNA-MEG3 in patients with primary liver cancer had close relationship with clinical stage, differentiation degree and cirrhosis (P<0.05), but no relationship with gender, age or tumor diameter (P>0.05). The 3-year survival rate in the low expression group of serum LncRNA-MEG3 was significantly lower than that in the high expression group (P<0.05). Cox regression analysis showed that low expression of LncRNA-MEG3 and clinical stage were independent risk factors for the prognosis of patients with primary liver cancer (HR=2.500, 95% CI: 1.624-3.849; HR=2.024, 95% CI: 1.307-3.135). Conclusion The serum expression level of LncRNA-MEG3 is significantly decreased in patients with primary liver cancer, and it is closely related to the clinical stage, differentiation degree, liver cirrhosis and prognosis of patients. It suggests that LncRNA-MEG3 may be a potential index for the disease assessment and the prognosis prediction of primary liver cancer.

Key words: Primary liver cancer, Long non-coding RNA maternally expressed gene 3, Clinicopathological characteristics, Prognosis

侯亚萍, 张小晶, 李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系[J]. 肝脏, 2021, 26(7): 757-760.

HOU Ya-ping, ZHANG Xiao-jing, LI Ting. The relationship between the expression of LncRNA-MEG3 and clinicopathological features, prognosis of patients with primary liver cancer[J]. Chinese Hepatolgy, 2021, 26(7): 757-760.

参考文献

[1] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 2018, 67:600-611.
[2] 宋晓婷, 国娇, 谭顺顺, 等. 血清QSOX-1、GSN、AFP联合检测对原发性肝癌的诊断价值. 山东医药, 2018, 58:54-56.
[3] Zhu X, Li H, et al. CREB-upregulated lncRNA MEG3 promotes hepatic gluconeogenesis by regulating miR-302a-3p-CRTC2 axis. J Cell Biochem, 2018, 120:4192-4202.
[4] 郑志刚, 韩军, 廖继红. 小细胞肺癌组织中lncRNA MEG3的表达及其与预后关系的研究. 临床肿瘤学杂志, 2017, 22:17-21.
[5] 邓荣华, 黄进团, 谷欣. lncRNA MEG3对肝癌细胞增殖凋亡的影响及机制研究. 临床和实验医学杂志, 2017, 16:1363-1366.
[6] Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more“personalized”approach to cancer staging. CA Cancer J Clin, 2017, 67:93-99.
[7] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肝胆病杂志, 2011, 27:1141-1159.
[8] 雷海科, 李小升, 赵玉兰, 等. 原发性肝癌患者生存预后及影响因素分析(附3106例报告). 中华消化外科杂志, 2020, 19:179-184.
[9] Liu Z, Jiang Y. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol, 2018, 70:674-683.
[10] 张志伟, 陈孝平. 《原发性肝癌诊疗规范》(2017版)解读. 临床外科杂志, 2018, 26:5-8.
[11] 毕明瑜, 戴文珠, 胡斐, 等. 长链非编码RNAs(LncRNAs)在人类乳腺癌中的研究现状. 中国细胞生物学学报, 2018, 40:1057-1064.
[12] 潘高峰, 周雪峰, 赵金平. 长链非编码RNA ZXF1表达与肺腺癌预后的关系及相关分子机制. 中华肿瘤杂志, 2017, 39:102-108.
[13] 方长英, 朱传卫, 张青松, 等. 原发性肝癌组织中长链非编码RNA外泌体复合物7的表达及临床意义. 临床肝胆病杂志, 2019, 35:124-127.
[14] Zhou C, Huang C, Wang J, et al. LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1α translation. Oncogene, 2017, 36:3878-3889.
[15] 郭苹, 程鹏, 王鹏飞, 等. LncRNA-MEG3对胃癌生物学特性及铂类化疗敏感性的研究. 中国现代医学杂志, 2019, 29:22-27.
[16] 孙旭, 孙丽芳, 于敏, 等. lncRNA MEG3通过下调miR-7-5p表达对鼻咽癌细胞放射敏感性的影响. 中华放射肿瘤学杂志, 2020, 29:207-210.
[17] 陈晓雷, 杨秀丽, 周天竹, 等. 雷公藤红素上调lncRNA MEG3表达抑制肝癌细胞增殖及促进细胞凋亡. 现代肿瘤医学, 2019, 27:739-742.